SpecialtiesQuestion

Would you consider SGLT2i therapy as a second line agent for treatment of HNF1A-MODY (MODY 3)?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Is the accuracy of continuous glucose monitors (DEXCOM or Libre) lower in patients undergoing dialysis?

In patients with MASLD, would you consider management with off-label metformin, pioglitazone (despite weight gain risk), GLP-1 RA, or simply intensify lifestyle and monitor?

What are your recommendations for natural light exposure in the management of type 2 diabetes, considering evidence from a randomized, crossover trial showing metabolic benefits?

Which antidiabetic agents would you recommend to treat hyperglycemia secondary to PI3K and AKT inhibitor therapy?

For which patients with type 2 diabetes mellitus would you consider switching to once-weekly basal insulin (Awiqli)?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.